By DengYueMed International Business DivisionToday, DengYueMed shares key commercial insights into China’s EGFR small-molecule targeted therapy market with international buyers and distribution partners. Drawing on the latest publicly available data, we analyzed the sales trends ...Learn More

As November 2025 arrives, the global pharmaceutical industry stands at a pivotal moment.In October alone, China saw six innovative drugs approved for market launch, including the world’s first EGFR-targeting Antibody–Drug Conjugate (ADC), Becotatugvedotin for Injection.This ...Learn More

Antibody–Drug Conjugates (ADCs): Leading the Global Oncology RevolutionAs cancer treatment enters the era of precision and personalization, Antibody–Drug Conjugates (ADCs)—often referred to as “biological missiles”—represent one of the highest frontiers of ...Learn More

China’s innovative drug sector has notched another record-breaking milestone as Innovent Biologics announced a partnership worth up to $11.4 billion with Takeda Pharmaceutical.According to the agreement, Innovent will receive a $1.2 billion upfront payment, including a $100 ...Learn More

Berlin, Germany — The annual European Society for Medical Oncology (ESMO) Congress, held from October 17–21, became a stage for China’s rapid ascent in pharmaceutical innovation. This year, Chinese biotech companies achieved record participation, with 35 studies accepted for ...Learn More